Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Accelerated Aging
10%
Allergic Response
8%
Arm
12%
Body Image
11%
Breast Cancer
56%
Cancer in Young Adults
100%
Cancer Prevention
10%
Cancer Prognosis
10%
Cancer Registry
19%
Cancer Research
20%
Cancer Risk
10%
Cancer Therapy
11%
Cardiotoxicity
10%
Care Pathway
10%
Cetirizine
10%
Clemastine
10%
Clinical Trial
13%
Clinician
10%
COVID-19
20%
Cryopreservation
8%
Cyclophosphamide
10%
Diseases
14%
Doxorubicin
10%
Emergency Care
10%
Emergency Department
10%
Estrogen Receptor
10%
Fertility Preservation
10%
Gene Expression
10%
H1 Antagonist
10%
Health Outcomes
15%
Histamine H1 Receptor
10%
Intracranial Tumor
10%
Malignant Neoplasm
71%
Metastatic Breast Cancer
20%
Monotherapy
10%
Neoplasm
18%
Neurofibromatosis Type I
10%
Paclitaxel
10%
Patient-Reported Outcome
20%
Premedication
10%
Quality of Life
76%
Receptor
11%
Recurrence Free Survival
10%
Reproductive Medicine
10%
Second Cancer
10%
Social Interaction
10%
Targeted Therapy
10%
Tipiracil
10%
Trametinib
10%
Trastuzumab
10%
Pharmacology, Toxicology and Pharmaceutical Science
Allergic Reaction
8%
Anthracycline
10%
Breast Cancer
25%
Cancer Registry
5%
Cardiotoxicity
10%
Cetirizine
10%
Chemotherapy
6%
Clemastine
10%
Clinical Trial
11%
Cyclophosphamide
10%
Doxorubicin
10%
Endoxifen
10%
Estrogen Receptor
10%
Histamine H1 Receptor
10%
Histamine H1 Receptor Antagonist
10%
Idarubicin
5%
Intracranial Tumor
10%
Malignant Neoplasm
38%
Metastatic Breast Cancer
20%
Mitoxantrone
5%
Neoplasm
6%
Paclitaxel
10%
Receptor
11%
Recurrence Free Survival
10%
Ribociclib
10%
Tamoxifen
10%
Taxane
11%
Tipiracil
10%
Trastuzumab
10%
Trifluridine
10%
Triple Negative Breast Cancer
5%
Nursing and Health Professions
Adolescent
6%
Breast Cancer
12%
Cancer Prevention
10%
Cancer Registry
5%
Cancer Research
10%
Care Pathway
10%
Cryopreservation
9%
Emergency Care
11%
Emergency Ward
20%
Fertility Preservation
10%
Germ Cell Tumor
6%
Length of Stay
6%
Malignant Neoplasm
45%
Oncologist
5%
Quality of Life
12%
Systematic Review
10%
